Heparegenix GmbH
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2038
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 22, 2027The maintenance fee for Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (US 11,731,968) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (US 11,858,927) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (US 11,912,701) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,040,027 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death In force · From the USPTO record | In force | From the USPTO record | |
| US 12,264,158 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death In force · From the USPTO record | In force | From the USPTO record | |
| US 11,858,927 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death In force · From the USPTO record | In force | From the USPTO record | |
| US 11,731,968 | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death In force · From the USPTO record | In force | From the USPTO record | |
| US 11,912,701 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death In force · From the USPTO record | In force | From the USPTO record | |
| US 12,466,826 | 3-Benzoyl-1H-pyrrolo[2,3-b]pyridine Derivatives as MKK4 Inhibitors for Treating Liver Diseases In force · Medium confidence | In force | Medium confidence | |
| US 12,643,895 | Heteroaryl-Substituted Pyrazolo-Pyridine Protein Kinase Inhibitors for Promoting Liver Regeneration or Reducing or Preventing Hepatocyte Death In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending